How advanced medicines commercial readiness differs from traditional drug launches.
Cell and gene therapies represent tremendous potential advancement for patient care, with the first therapy approved in 2017 they have only recently become available. As we enter 2023, a half-decade after the first FDA approved Cell and Gene Therapy (CGT), some of the few pioneers of these therapies with curative intent
are not meeting commercial expectations. While reasons for underperformance vary, the common thread that weaves throughout is the degree of commercial and/or launch planning readiness established prior to anticipated approval.